Literature DB >> 2412918

Prevention of defective axonal transport in streptozocin-diabetic rats by treatment with "Statil" (ICI 128436), an aldose reductase inhibitor.

D R Tomlinson, J Townsend, P Fretten.   

Abstract

This investigation examined the effect of treatment of streptozocin-diabetic rats with the aldose reductase inhibitor "Statil" (25 mg/kg/day p.o.) on axonal transport in cholinergic neurons of the sciatic and vagal nerves and on nerve polyol and sugar levels. Three weeks of experimental diabetes caused deficits in the accumulation of choline acetyltransferase activity proximal to 24-h constrictions in the left sciatic and vagus nerves. These deficits did not develop in age-matched, similarly diabetic rats that were treated with the aldose reductase inhibitor. The inhibitor prevented completely the build-up of sorbitol and markedly reduced the build-up of fructose in the sciatic nerves of the treated diabetic rats. The inhibitor also prevented the depletion of myo-inositol that was seen in the untreated diabetic animals. It is suggested that these findings indicate a possible approach to the elucidation of the pathogenesis of cardiac vagal dysfunction in diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2412918     DOI: 10.2337/diab.34.10.970

Source DB:  PubMed          Journal:  Diabetes        ISSN: 0012-1797            Impact factor:   9.461


  12 in total

Review 1.  Aldose reductase inhibitors and late complications of diabetes.

Authors:  P Benfield
Journal:  Drugs       Date:  1986       Impact factor: 9.546

2.  Age-dependent slowing of enteric axonal transport in insulin-resistant mice.

Authors:  Kathy J LePard; Joseph Cellini
Journal:  World J Gastroenterol       Date:  2013-01-28       Impact factor: 5.742

3.  Treatment with an aldose reductase inhibitor can reduce the susceptibility of fast axonal transport following nerve compression in the streptozotocin-diabetic rat.

Authors:  L B Dahlin; D R Archer; W G McLean
Journal:  Diabetologia       Date:  1987-06       Impact factor: 10.122

4.  Preventive effect of long-term aldose reductase inhibition (ponalrestat) on nerve conduction and sural nerve structure in the spontaneously diabetic Bio-Breeding rat.

Authors:  A A Sima; A Prashar; W X Zhang; S Chakrabarti; D A Greene
Journal:  J Clin Invest       Date:  1990-05       Impact factor: 14.808

Review 5.  The biochemistry of diabetes.

Authors:  R Taylor; L Agius
Journal:  Biochem J       Date:  1988-03-15       Impact factor: 3.857

6.  Small intestinal morphology in experimental diabetic rats: a stereological study on the effects of an aldose reductase inhibitor (ponalrestat) given with or without conventional insulin therapy.

Authors:  T M Mayhew; F L Carson; A K Sharma
Journal:  Diabetologia       Date:  1989-09       Impact factor: 10.122

7.  Impaired induction of nerve ornithine decarboxylase activity in the streptozotocin-diabetic rat is prevented by the aldose reductase inhibitor ponalrestat.

Authors:  C Pekiner; W G McLean
Journal:  Br J Pharmacol       Date:  1990-12       Impact factor: 8.739

8.  Administration of an aldose reductase inhibitor induces a decrease of collagen fluorescence in diabetic rats.

Authors:  G Suárez; R Rajaram; K C Bhuyan; A L Oronsky; J A Goidl
Journal:  J Clin Invest       Date:  1988-08       Impact factor: 14.808

9.  The preventive effect of aldose reductase inhibition on diabetic optic neuropathy in the BB/W-rat.

Authors:  M Kamijo; P V Cherian; A A Sima
Journal:  Diabetologia       Date:  1993-10       Impact factor: 10.122

10.  Prevention of defects of axonal transport in experimental diabetes by aldose reductase inhibitors.

Authors:  D R Tomlinson; G B Willars; J P Robinson
Journal:  Drugs       Date:  1986       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.